Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2015

View Archived Issues

Adapt Pharma successfully completes pharmacokinetic study of intranasal naloxone

VolitionRx and Hvidovre Hospital initiate trial to identify NuQ biomarkers for colorectal polyps

Biohaven advancing BHV-0223 toward phase I trial

Enrollment open in phase II study of GI-6301 for chordoma

European CANCER-ID consortium formed to validate blood biomarkers of cancer

Shanghai De Novo Pharmatech characterizes AML candidate SC-110237

Clinical data reported for antibody-drug conjugate SGN-CD33A

ThromboGenics starts developing Jetrea for retinal vein occlusion

Janssen seeks Japanese approval of Risperdal for irritability in children with autistic disorder

Karus Therapeutics presents PI3Kbeta/delta inhibitors

U.S. orphan drug designation awarded to Dicerna's DCR-PH1 for primary hyperoxaluria type 1

Celgene and MedImmune collaborate to develop MEDI-4736 for hematologic malignancies

Bayer patents FXIa inhibitors

Bayer seeks Japanese approval for radium-223 dichloride

Janssen Pharmaceutica discloses NIK inhibitors

Cortendo reports development of novel cytochrome P450 inhibitors

Korean researchers present HRP-3 inhibitors

Roche divulges new tau-imaging compounds

FDA approves label update to Pomalyst

Aerie reports results from first registrational study of Rhopressa

FDA grants priority review to idarucizumab BLA

World Malaria Day: unveiling parasite resistance mechanisms

Actavis launches Avycaz in U.S.

AstraZeneca and Innate Pharma collaborate on development of IPH-2201

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...